Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1

Interventions

Oxaliplatin 10Capecitabine 9Cisplatin 8Fluorouracil 5Leucovorin 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3atezolizumab 3Nivolumab 3trebananib 2ponatinib 2pembrolizumab 2avelumab 2apatinib 2alectinib 2XELOX 2Standard of Care 2S 1 (combination) 2Radiotherapy 2Radiosurgery 2Ocoxin 2Irinotecan 2Ipilimumab 2Gemcitabine 2Folfox protocol 2Everolimus 2Erlotinib Hydrochloride 2Acupuncture Therapy 2zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Neoplasms × Pafolacianine × Clear all
NCT07039526 2026-06-05

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.

University of Texas Southwestern Medical Center

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Esophageal Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡